Beleaguered Arrowhead 'Cautiously Optimistic' About RNAi Deal, Closes Calando's Lab | GenomeWeb

By Doug Macron

This story has been updated to include details about Arrowhead's compliance with the Nasdaq's minimum stockholders' equity requirement.

Arrowhead Research's top official this week said that the firm's Calando Pharmaceuticals subsidiary continues to look for a partner for its RNAi drug-delivery system and clinical candidate, and that he is "cautiously optimistic" that pending phase I data on the drug will help drive a deal.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.